BIO-TECHNE Corp Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-06-30: PEO Mr. Kelderman; Other NEO average total compensation $3.75M.
- 2024-06-30: PEO Mr. Kelderman; Other NEO average total compensation $3.30M.
- 2023-06-30: PEO Mr. Kummeth; Other NEO average total compensation $2.26M.
- 2022-06-30: PEO Mr. Kummeth; Other NEO average total compensation $3.22M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | Mr. Kelderman | $3.75M | $2.88M | $79.49 | $103.58 | $73.40M | organic revenue $1.21M | 2025-09-19 | ||
| 2024-06-30 | Mr. Kelderman | $3.30M | $3.65M | $110.17 | $131.47 | $168.10M | $1.15M | 2025-09-19 | ||
| 2023-06-30 | Mr. Kummeth | $2.26M | $2.42M | $124.96 | $126.72 | $285.44M | $1.13M | 2025-09-19 | ||
| 2022-06-30 | Mr. Kummeth | $3.22M | -$2.68M | $132.17 | $129.72 | $263.10M | $1.11M | 2025-09-19 | ||
| 2021-06-30 | Mr. Kummeth | $4.95M | $26.44M | $171.17 | $147.61 | $139.59M | $915.90K | 2025-09-19 | ||
| 2024-06-30 | $12.30M | $4.15M | $110.17 | $131.47 | $168.10M | organic revenue $1.14M | 2024-09-12 | |||
| 2023-06-30 | $30.58M | $4.68M | $2.26M | $2.42M | $124.96 | $126.72 | $285.44M | $1.13M | 2024-09-12 | |
| 2022-06-30 | $15.37M | -$6.35M | $3.22M | -$2.68M | $132.17 | $129.72 | $263.10M | $1.11M | 2024-09-12 | |
| 2021-06-30 | $15.89M | $105.68M | $4.95M | $26.44M | $171.17 | $147.61 | $139.59M | $915.90K | 2024-09-12 | |
| 2023-06-30 | Charles Kummeth | $30.58M | $4.68M | $2.26M | $2.42M | $124.96 | $126.72 | $285.44M | organic revenue $1.13M | 2023-09-13 |
| 2022-06-30 | Charles Kummeth | $15.37M | -$6.35M | $3.22M | -$2.68M | $132.17 | $129.72 | $263.10M | $1.11M | 2023-09-13 |
| 2021-06-30 | Charles Kummeth | $15.89M | $105.68M | $4.95M | $26.44M | $171.17 | $147.61 | $139.59M | $915.90K | 2023-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |